Objectives: To characterize the population pharmacokinetics of piperacillin and tazobactam
in critically ill infants and children, in order to develop an evidence-based dosing regimen …

Objectives To develop population pharmacokinetic (PK) models for piperacillin/tazobactam
in neonates and infants of less than 2 months of age in order to determine the appropriate …

Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections
in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of extended-infusion piperacillin-tazobactam in children hospitalized in …

The pharmacokinetics of piperacillin and tazobactam were assessed after single-dose
administration to 47 infants and children. Study subjects ranging in age from 2 months to 12 …

Piperacillin/tazobactam, an intravenous antibacterial combination product, has recently
been approved for paediatric (age 2 months to 17 years) use in the USA. The purpose of this …

Methods: Blood samples (2–4 per child) were collected from 13 children ages 9 months to 6
years admitted to the pediatric intensive care unit who were receiving standard piperacillin …

BACKGROUND: Use of extended infusions of piperacillin/tazobactam (PT) in adult patients
has been described, but data in children are limited. OBJECTIVE: The goal of this study was …

Objectives To be effective, piperacillin/tazobactam (PTZ) unbound plasma levels need to be
above the minimum inhibitory concentration (MIC) at least 50% of the time between dosing …

An open, non-comparative study was designed to evaluate the safety and toler-ance of
parenteral piperacillin/tazobactam in very low birth weight infants. Twenty-seven patients …